On July 17, 2020 Sunshine Guojian Pharma (Shanghai), a 3SBio subsidiary that develops antibody drugs, reported that it is planning a $248 million IPO on the Shanghai STAR Market (Press release, Sunshine Guojian Pharmaceutical, JUL 17, 2020, View Source [SID1234562030]). Founded in 2002, Sunshine Guojian has two marketed antibody products and is developing 15 more, several of which have completed Phase III trials. The company develops novel and biosimilar products. It claims to have the largest antibody production base of of any China biopharma with total capacity of more than 38,000 liters.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!